Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,intangibleAssets,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,otherCurrentAssets,retainedEarnings,cash,totalCurrentLiabilities,propertyPlantEquipment,totalCurrentAssets,accountsPayable,changeToLiabilities,netBorrowings,totalCashFromFinancingActivities,changeToOperatingActivities,changeInCash,totalCashFromOperatingActivities,depreciation,otherCashflowsFromFinancingActivities,changeToNetincome,totalCashflowsFromInvestingActivities,capitalExpenditures,WC,language,region,quoteType,triggerable,quoteSourceName,currency,esgPopulated,tradeable,exchangeDataDelayedBy,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,epsTrailingTwelveMonths,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,marketCap,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,priceHint,exchange,marketState,market,shortName,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,Shares Short 4,Short Ratio 4,Short % of Float 4,Short % of Shares Outstanding 4,Shares Short (prior month ) 4,Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,longBusinessSummary,city,phone,state,compensationAsOfEpochDate,country,website,maxAge,address1,industry,address2
t0,FPMI,-10464238,34262300,103890,,-127234,,-127234,417580,0,-521470,-521470,,-196460,,,,0,0,521470,0,394236,,-127234,-252163,279553,24958880,10514052,-10184685,2428972,334760,34075,3022,-35177640,24723,10514052,7424,47783,1413874,317722.0,115000.0,113460.0,52720.0,-2779.0,-116239.0,10875.0,-1540.0,-569294.0,,,-10466269,en-US,US,EQUITY,False,Delayed Quote,USD,False,False,0,0.0033999998,2.125,0.0016 - 0.079,-0.074,-0.9367088,0.0016,0.079,-0.077,0.0,0.005 - 0.005,0.005,0.0,0.0,0,0,finmb_22727382,Other OTC,"FluoroPharma Medical, Inc.",USD,309078,219192,-0.299,0.006285,-0.0012850002,-0.20445509,0.010195,-0.005195,-0.5095635,2454315,-0.016722407,15,America/New_York,EDT,-14400000,4,PNK,POST,us_market,FLUOROPHARMA MEDICAL INC,0.005,1630007517,0.0,0.0041,0.005,0.005,1200156,1.19,,,0.079,0.0016,0.0063,0.0102,309.08k,219.19k,34.26M,,30.66M,0.00%,2.69%,,,,,,,,,,,0.00%,,,,,"Dec 30, 2016","Dec 30, 2016",0.00%,0.00%,-234.63%,,,,,,-2.16M,-2.57M,-0.0770,,24.72k,0,5.82M,,0.00,-0.30,-880.12k,-780.87k,Value,07042,Healthcare,4,"FluoroPharma Medical, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of molecular imaging pharmaceuticals with initial applications in the area of cardiology in the United States. Its product candidates include BFPET, an imaging agent that has completed a Phase I clinical trial in stress-testing for patients with presumptive or proven coronary artery disease (CAD); and CardioPET, a molecular imaging agent, which is in Phase IIa clinical trial to assess myocardial blood flow and metabolism in patients with CAD. The company has license agreements with Massachusetts General Hospital and Sinotau USA; and clinical research agreements with Pharmaceutical Product Development, LLC, as well as Cardiovascular Imaging Technologies. FluoroPharma Medical, Inc. was founded in 2003 and is headquartered in Montclair, New Jersey.",Montclair,973-744-1565,NJ,1483142400,United States,http://www.fluoropharma.com,86400,8 Hillside Avenue,Biotechnology,Suite 108
t-1,FPMI,-10226684,34262300,-21836,,384107,,384107,341457,0,-319621,-319621,,-212892,,,,0,0,319621,0,703728,,384107,251398,289301,24954234,10319188,-9937383,2696894,387266,33860,42421,-34925477,27502,10319188,8551,89414,1322715,6733.0,150000.0,149230.0,-131989.0,-380807.0,-530037.0,11061.0,-770.0,-879874.0,,,-10229774,en-US,US,EQUITY,False,Delayed Quote,USD,False,False,0,0.0033999998,2.125,0.0016 - 0.079,-0.074,-0.9367088,0.0016,0.079,-0.077,0.0,0.005 - 0.005,0.005,0.0,0.0,0,0,finmb_22727382,Other OTC,"FluoroPharma Medical, Inc.",USD,309078,219192,-0.299,0.006285,-0.0012850002,-0.20445509,0.010195,-0.005195,-0.5095635,2454315,-0.016722407,15,America/New_York,EDT,-14400000,4,PNK,POST,us_market,FLUOROPHARMA MEDICAL INC,0.005,1630007517,0.0,0.0041,0.005,0.005,1200156,1.19,,,0.079,0.0016,0.0063,0.0102,309.08k,219.19k,34.26M,,30.66M,0.00%,2.69%,,,,,,,,,,,0.00%,,,,,"Dec 30, 2016","Dec 30, 2016",0.00%,0.00%,-234.63%,,,,,,-2.16M,-2.57M,-0.0770,,24.72k,0,5.82M,,0.00,-0.30,-880.12k,-780.87k,Value,07042,Healthcare,4,"FluoroPharma Medical, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of molecular imaging pharmaceuticals with initial applications in the area of cardiology in the United States. Its product candidates include BFPET, an imaging agent that has completed a Phase I clinical trial in stress-testing for patients with presumptive or proven coronary artery disease (CAD); and CardioPET, a molecular imaging agent, which is in Phase IIa clinical trial to assess myocardial blood flow and metabolism in patients with CAD. The company has license agreements with Massachusetts General Hospital and Sinotau USA; and clinical research agreements with Pharmaceutical Product Development, LLC, as well as Cardiovascular Imaging Technologies. FluoroPharma Medical, Inc. was founded in 2003 and is headquartered in Montclair, New Jersey.",Montclair,973-744-1565,NJ,1483142400,United States,http://www.fluoropharma.com,86400,8 Hillside Avenue,Biotechnology,Suite 108
t-2,FPMI,-10493399,34262300,239667,,-734100,,-734100,439700,0,-679367,-679367,,-456031,,,,0,0,679367,0,-54733,,-734100,-866998,299049,24948875,10961403,-10194350,3631633,772584,33650,36419,-35176875,408309,10961403,9863,463672,1400464,285549.0,210000.0,208460.0,679229.0,367137.0,159970.0,11024.0,-1540.0,-289344.0,-1293.0,-1293.0,-10497731,en-US,US,EQUITY,False,Delayed Quote,USD,False,False,0,0.0033999998,2.125,0.0016 - 0.079,-0.074,-0.9367088,0.0016,0.079,-0.077,0.0,0.005 - 0.005,0.005,0.0,0.0,0,0,finmb_22727382,Other OTC,"FluoroPharma Medical, Inc.",USD,309078,219192,-0.299,0.006285,-0.0012850002,-0.20445509,0.010195,-0.005195,-0.5095635,2454315,-0.016722407,15,America/New_York,EDT,-14400000,4,PNK,POST,us_market,FLUOROPHARMA MEDICAL INC,0.005,1630007517,0.0,0.0041,0.005,0.005,1200156,1.19,,,0.079,0.0016,0.0063,0.0102,309.08k,219.19k,34.26M,,30.66M,0.00%,2.69%,,,,,,,,,,,0.00%,,,,,"Dec 30, 2016","Dec 30, 2016",0.00%,0.00%,-234.63%,,,,,,-2.16M,-2.57M,-0.0770,,24.72k,0,5.82M,,0.00,-0.30,-880.12k,-780.87k,Value,07042,Healthcare,4,"FluoroPharma Medical, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of molecular imaging pharmaceuticals with initial applications in the area of cardiology in the United States. Its product candidates include BFPET, an imaging agent that has completed a Phase I clinical trial in stress-testing for patients with presumptive or proven coronary artery disease (CAD); and CardioPET, a molecular imaging agent, which is in Phase IIa clinical trial to assess myocardial blood flow and metabolism in patients with CAD. The company has license agreements with Massachusetts General Hospital and Sinotau USA; and clinical research agreements with Pharmaceutical Product Development, LLC, as well as Cardiovascular Imaging Technologies. FluoroPharma Medical, Inc. was founded in 2003 and is headquartered in Montclair, New Jersey.",Montclair,973-744-1565,NJ,1483142400,United States,http://www.fluoropharma.com,86400,8 Hillside Avenue,Biotechnology,Suite 108
t-3,FPMI,-9769051,34262300,189660,,-1572634,,-1572634,492311,0,-681971,-681971,,-399076,,,,0,0,681971,0,-890663,,-1572634,-1705503,308799,24816404,9911586,-9460252,3252097,456858,33221,79726,-34309877,41172,9911586,9845,138214,1298248,121193.0,150000.0,144140.0,200502.0,-249675.0,-393815.0,10952.0,-5860.0,580997.0,-1293.0,-1293.0,-9773372,en-US,US,EQUITY,False,Delayed Quote,USD,False,False,0,0.0033999998,2.125,0.0016 - 0.079,-0.074,-0.9367088,0.0016,0.079,-0.077,0.0,0.005 - 0.005,0.005,0.0,0.0,0,0,finmb_22727382,Other OTC,"FluoroPharma Medical, Inc.",USD,309078,219192,-0.299,0.006285,-0.0012850002,-0.20445509,0.010195,-0.005195,-0.5095635,2454315,-0.016722407,15,America/New_York,EDT,-14400000,4,PNK,POST,us_market,FLUOROPHARMA MEDICAL INC,0.005,1630007517,0.0,0.0041,0.005,0.005,1200156,1.19,,,0.079,0.0016,0.0063,0.0102,309.08k,219.19k,34.26M,,30.66M,0.00%,2.69%,,,,,,,,,,,0.00%,,,,,"Dec 30, 2016","Dec 30, 2016",0.00%,0.00%,-234.63%,,,,,,-2.16M,-2.57M,-0.0770,,24.72k,0,5.82M,,0.00,-0.30,-880.12k,-780.87k,Value,07042,Healthcare,4,"FluoroPharma Medical, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of molecular imaging pharmaceuticals with initial applications in the area of cardiology in the United States. Its product candidates include BFPET, an imaging agent that has completed a Phase I clinical trial in stress-testing for patients with presumptive or proven coronary artery disease (CAD); and CardioPET, a molecular imaging agent, which is in Phase IIa clinical trial to assess myocardial blood flow and metabolism in patients with CAD. The company has license agreements with Massachusetts General Hospital and Sinotau USA; and clinical research agreements with Pharmaceutical Product Development, LLC, as well as Cardiovascular Imaging Technologies. FluoroPharma Medical, Inc. was founded in 2003 and is headquartered in Montclair, New Jersey.",Montclair,973-744-1565,NJ,1483142400,United States,http://www.fluoropharma.com,86400,8 Hillside Avenue,Biotechnology,Suite 108
